|
Levemir insulin is a form of long acting insulin
detamir. It is different from most other long acting insulin, because it
is more slowly absorbed and therefore the effects of the dose can last
longer up to 24 hours in duration. It should be used in combination with
short or rapid acting insulin, given at meal times, to achieve good
glycaemic control. For further details, read The
Medical Way Out Of Type 1 And Type 2 Diabetes.
Diabetes is a condition in which the body does not produce or
properly use the insulin. It affects 18.2 million people in the U.S.
alone. Diabetes type 1 is a result of body's failure to produce insulin,
the hormone that unlocks the cells of the body, allowing glucose to
enter and fuel them. It is estimated that 5-10 percent of Americans who
are diagnosed with diabetes have type 1 diabetes. Type 2 diabetes
results from insulin resistance, combined with relative insulin
deficiency. Most Americans who are diagnosed with diabetes have type 2 diabetes.
Levemir insulin is marked for once or twice daily
subcutaneous injection, depending on the blood glucose control and
insulin requirements throughout the day. Levemir insulin provides a
relatively flat action profile. Levemir can be used in mono therapy,
added to oral anti-diabetic agents, or in combination with a
rapid-acting insulin. Levemir insulin has already been approved for use
in US by the American Diabetes Association. Hypoglycemia is the most
common adverse effect of levemir insulin. Adverse effects commonly
associated with human insulin therapy include allergic reactions,
injection site reaction, lipodystrophy, pruritus, and rash. Levemir is
not meant for use by patients hypersensitive to insulin detemir or its excipients.
|
